<code id='19AB652DD0'></code><style id='19AB652DD0'></style>
    • <acronym id='19AB652DD0'></acronym>
      <center id='19AB652DD0'><center id='19AB652DD0'><tfoot id='19AB652DD0'></tfoot></center><abbr id='19AB652DD0'><dir id='19AB652DD0'><tfoot id='19AB652DD0'></tfoot><noframes id='19AB652DD0'>

    • <optgroup id='19AB652DD0'><strike id='19AB652DD0'><sup id='19AB652DD0'></sup></strike><code id='19AB652DD0'></code></optgroup>
        1. <b id='19AB652DD0'><label id='19AB652DD0'><select id='19AB652DD0'><dt id='19AB652DD0'><span id='19AB652DD0'></span></dt></select></label></b><u id='19AB652DD0'></u>
          <i id='19AB652DD0'><strike id='19AB652DD0'><tt id='19AB652DD0'><pre id='19AB652DD0'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:entertainment    - browse:28354
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus